Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical
  • Published:

Deciphering novel chemotherapy and its impact on dentistry

British Dental Journal volume 228, pages 415–421 (2020)Cite this article

Abstract

In the last few decades, the number of targeted chemotherapies approved for cancer treatment and undergoing clinical trials has risen. In comparison to conventional chemotherapy, targeted therapies (TTs) act on specific molecular targets involved in cancer development and progression, with reduced detrimental effects to normal tissues. TTs have now been recognised as key treatments in a number of common cancers, including solid tumours and haematological malignancies. The number of patients undergoing novel cancer treatment will continue to increase, and a significant population will likely present to the dental environment. This paper aims to provide an insight into TTs currently available, including monoclonal antibodies, fusion proteins, tyrosine kinase inhibitors, histone deacetylase inhibitors, mammalian target of rapamycin inhibitors, phosphoinositide 3-kinase inhibitors, proteasome inhibitors and hedgehog pathway inhibitors. The mechanisms of action, indications for use and how to identify the medications will be summarised. Dental implications of these novel therapies include medication-related osteonecrosis of the jaw, delayed healing, immunosuppression and thrombocytopenia. These will be discussed to ensure oral healthcare providers are aware of their impact in a dental setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci 2017; 18: 1-25.

  2. Di Martino S, Rainone A, Troise A et al. Overview of FDA-Approved Anti Cancer Drugs Used for Targeted Therapy. World Cancer Res J 2015; 2: e553. Available online at https://www.wcrj.net/article/553 (accessed February 2020).

  3. Arora A, Scholar E M. Role of Tyrosine Kinase Inhibitors in Cancer Therapy. J Pharmacol Exp Ther 2005; 315: 971-979.

  4. National Cancer Institute. Targeted Cancer Therapies. 2018. Available at https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet (accessed October 2018).

  5. Research Advocacy Network. Targeted Therapies in Cancer. 2013. Available at http://www.researchadvocacy.org/sites/default/files/resources/TargetedTherapiesTutorial-Final.pdf (accessed October 2018).

  6. Office for National Statistics. Overview of the UK population: August 2019. 2019. Available at https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/august2019 (accessed October 2019).

  7. Cancer Research UK. Cancer diagnosis and treatment. Available at https://www.cancerresearchuk.org/health-professional/cancer-statistics/diagnosisandtreatment#heading-Three (accessed October 2019).

  8. Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 209-227.

  9. Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J 2014; 63: 650-654.

  10. American Cancer Society. Monoclonal antibodies and their side effects. Available at https://www.cancer.org/treatment/treatmentsandside-effects/treatment-types/immunotherapy/monoclonal-antibodies.html (accessed May 2018).

  11. World Health Organisation. Revised monoclonal antibody (mAb) nomenclature scheme. 2017. Available at: http://www.who.int/medicines/services/inn/Revised_mAb_nomenclature_scheme.pdf (accessed May 2018).

  12. Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.

  13. You Tm, Lee K H, Lee S H, Park W. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 548-553.

  14. Malan J, Ettinger K, Naumann E, Beirne O R. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 671-676.

  15. Zhang X, Hamadeh I S, Song S et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). J Bone Miner Res 2016; 31: 336-340.

  16. Estilo C L, Fornier M, Farooki A, Carlson D, Bohle G, Huryn J M. Osteonecrosis of the Jaw Related to Bevacizumab. J Clin Oncol 2008; 26: 4037-4038.

  17. Erovigni F, Gambino A, Cabras M et al. Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent J (Basel) 2016; 4: 39.

  18. Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188.

  19. Weigert K L, Lewgoy J, Mazzoleni D S, Franco F R, Enriconi L, Henrique Sasso J. Rituximab and Osteonecrosis of the Jaws: Case Study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; DOI: 10.1016/j.oooo.2013.12.203.

  20. Allegra A, Oteri G, Alonci A et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg 2014; 42: 279-282.

  21. Kerbin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. J Oral Maxillofac Surg 2017; 75: 2599-2605.

  22. Cassoni A, Romeo U, Terenzi V et al. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case Rep Dent 2016; DOI: 10.1155/2016/2856926.

  23. Favia G, Tempesta A, Limongelli L et al. A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. Am J Case Rep 2017; 18: 1351-1356.

  24. Cosman F, Crittenden D B, Adachi J D et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375: 1532-1543.

  25. Saag K G, Peterson J, Luisa Brandi M et al. Romosozumab or Alendronate for.Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-1427.

  26. National Cancer Institute. Angiogenesis Inhibitors. 2018. Available at https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet (accessed May 2018).

  27. Riggs P, La Vallie E R, McCoy J M. Introduction to expression by fusion protein vectors. Curr Protoc Mol Biol 2001; DOI: 10.1002/0471142727.mb1604as28.

  28. NICE. AFLIBERCEPT. Available at https://bnf.nice.org.uk/drug/aflibercept.html (accessed May 2018).

  29. Tabernero J, Van Cutsem E, Lakomý R et al. Aflibercept Versus Placebo in Combination With Irinotecan and 5FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR). Eur J Cancer 2014; 50: 320-331.

  30. Schmidt SR. Fusion proteins: Applications and Challenges. Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. 2013; pp 3. Hoboken, NJ: Wiley-Blackwell.

  31. Mawardi H, Enzinger P, McCleary N et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016; 7: 81-87.

  32. Medicines and Healthcare Products Regulatory Agency. Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw. 2016. Available at https://www.gov.uk/drug-safety-update/aflibercept-zaltrap-minimising-the-risk-of-osteonecrosis-of-the-jaw (accessed May 2018).

  33. Ponzetti A, Pinta F, Spadi R et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016; DOI: 10.5301/tj.5000405.

  34. Zarringhalam P, Brizman E, Shakib K. Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg 2017; 55: 314-315.

  35. Paul M K, Mukhopadhy A K. Tyrosine kinaserole and significance in cancer. Int J Med Sci 2004; 1: 101-115.

  36. Hartmann J T, Haap M, Kopp H G, Lipp H P. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 480-481.

  37. Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 209-227.

  38. NICE. Evidence Search. Tyrosine kinase inhibitor. Available at https://www.evidence.nhs.uk/search?q=Tyrosine+kinase+inhibitor (accessed May 2018).

  39. Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 2017; 43: 120-124.

  40. Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib - A case report with clinical implications. Forum Clin Oncol. 2013; 4: 29-33.

  41. Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Regorafenib Also Can Cause Osteonecrosis of the Jaw. J Natl Cancer Inst 2016; DOI: 10.1093/jnci/djw002.

  42. Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J 2015; 60: 528-531.

  43. Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-164.

  44. Allen M R, Burr D B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67: 61-70.

  45. Xie J, Wang X, Proud C G. mTOR inhibitors in cancer therapy. F1000Res 2016; DOI: 10.12688/f1000research.9207.1.

  46. Zheng Y, Jiang Y. mTOR Inhibitors at a Glance. Mol Cell Pharmacol 2015; 7: 15-20.

  47. Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. Br Dent J 2015; 219: 203-207.

  48. NICE. EVEROLIMUS. Available at https://bnf.nice.org.uk/drug/everolimus.html (accessed May 2018).

  49. NICE. TEMSIROLIMUS. Available at https://bnf.nice.org.uk/drug/temsirolimus.html (accessed May 2018)

  50. NICE. SIROLIMUS. Available at https://bnf.nice.org.uk/drug/sirolimus.html (accessed May 2018).

  51. NICE. TACROLIMUS. Available at https://bnf.nice.org.uk/drug/tacrolimus.html (accessed May 2018).

  52. Dancey J W, Monzon J. Ridaforolimus: a promising drug in the treatment of soft tissue sarcoma and other malignancies. Future Oncol 2011; 7: 827-839.

  53. Kneissel M, Luong-Nguyen N H, Baptist M et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35: 1144-1156.

  54. Lee C Y S, Lee K L, Hirata K Y, Suzuki J B. Medication-related osteonecrosis of the jaw with the mTOR inhibitor Everolimus in a patient with oestrogen-receptor positivie breast cancer: a case report. International J Oral Dent Health 2016; 2: 1-5.

  55. Yamamoto D, Tsubota Y, Utsunomiya T et al. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol 2017; 6: 255-257.

  56. Giancola F, Campisi G, Lo Russo L, Muzio L L, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: A unique case report? Ann Stomatol (Roma) 2013; 4: 20-21.

  57. Kim D W, Jung Y S, Park H S, Jung H D. Osteonecrosis of the jaw related to everolimus: A case report. Br J Oral Maxillofac Surg 2013; 51: 302-304.

  58. National Institute of Dental and Craniofacial Research. Dental Management of the Organ Transplant Patient. 2008. Available at https://www.in.gov/isdh/files/OrganTransplantProf.pdf (accessed October 2019).

  59. Ceccaci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer. 2016; 114: 605-611.

  60. Halsall J A, Turner B M. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success. Bioessays 2016; 38: 1102-1110.

  61. Subramanian S, Bates S E, Wright J J, Espinoza-Delgado I, Piekarz R L. Clinical Toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel) 2010; 3: 2751-2767.

  62. Wang X, Ding J, Meng L. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmal Sin 2015; 36: 1170-1176.

  63. Fruman D A, Rommel C. PI3K and Cancer: Lessons, Challenges and Opportunities. Nat Rev Drug Discov 2014; 13: 140-156.

  64. NICE. IDELALISIB. Available at https://bnf.nice.org.uk/drug/idelalisib.html (accessed October 2019).

  65. Crawford L J, Walker B, Irvine A E. Proteasome inhibitors in cancer therapy. J Cell Commun 2011; 5: 101-110.

  66. Shinohara K, Tomoika M, Nakano H, Tone S, Ito H, Kawahima S. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996; 317: 385-388.

  67. McConkey D J, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164-179.

  68. Nawrocki S T, Bruns C J, Harbison M T et al. Effects of the proteasome inhibitor PS341 on apoptosis and angiogenesis in orthotopic human pancreatic tumour xenografts. Mol Cancer Ther 2002; 1: 1243-1253.

  69. Kane R C, Farell A T, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12: 2955-2960.

  70. NICE. CARFILZOMIB. Available at https://bnf.nice.org.uk/drug/carfilzomib.html (accessed October 2019).

  71. NICE. IXAZOMIB. Available at https://bnf.nice.org.uk/drug/ixazomib.html (accessed October 2019).

  72. Nagao H, Ijiri K, Hirotsu M et al. Role of GLI2 in the growth of human osteosarcoma. J Pathol 2011; 224: 169-179.

  73. Ng J M, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.

  74. Gorlin R J, Goltz R W. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. N Engl J Med 1960; 262: 908-912.

  75. Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology and clinical utility for advanced basal cell carcinomas. Onco Targets Ther 2017; 10: 1645-1653.

  76. Sekulic A, Migden M R, Oro A E et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.

  77. Rimkus T K, Carpenter R L, Qasem S, Chan M, Lo H W. Targeting the Sonic Hedgehog Signalling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 2016; 8: 1-23.

  78. Kumar R M R, Fuchs B. Hedgehog Signalling Inhibitors as Anti-Cancer Agents in Osteosarcoma. Cancers (Basel) 2015; 7: 784-794.

  79. U.S. Department of Health and Human Services. Dental Provider's Pocket Oncology Guide. 2009. Available at https://www.nidcr.nih.gov/sites/default/files/2017-09/oncology-guide-dental-provider_0.pdf (accessed February 2020).

  80. Lopez B C, Esteve C G, Perez M G S. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent 2011; 3: 31-42.

  81. Cancer Research UK. Infection during or after treatment. 2019. Available at https://www.cancerresearchuk.org/about-cancer/coping/physically/fever/causes/infection/during-or-after-treatment (accessed November 2019).

  82. Chemocare: Nadir. Available at http://chemocare.com/chemotherapy/what-is-chemotherapy/what-is-nadir.aspx (accessed November 2019).

  83. King R, Tanna N, Patel V. Medication related osteonecrosis of the jaw unrelated to bisphosphonates and denosumaba review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289-299.

  84. Patel V, Mansi J, Ghosh S et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 2018; 224: 74-79.

  85. The Royal College of Surgeons of England. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation: Clinical Guidelines. 2018. Available online at https://www.rcseng.ac.uk/-/media/files/rcs/fds/publications/rcs-oncology-guideline-update--v36.pdf (accessed February 2020).

  86. Medicines and Healthcare Products Regulatory Agency. Denosumab: updated recommendations. 2014. Available at https://www.gov.uk/drugsafetyupdate/denosumabupdatedrecommendations (accessed January 2020).

  87. Medicines and Healthcare Products Regulatory Agency. Becavizumab and sunitinib: risk of osteonecrosis of the jaw. 2014. Available at https://www.gov.uk/drugsafetyupdate/bevacizumabandsunitinibriskofosteonecrosisofthejaw (accessed January 2020).

  88. Schuurhuis J M, Span L F, Stokman M A, van Winkelhoff A J, Vissink A, Spijkervet F K. Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy. Br J Cancer 2016; 114: 972-978.

  89. Vozza I, Caldarazzo V, Polimeni A, Ottolenghi L. Periodontal disease and cancer patients undergoing chemotherapy. Int Dent J 2015; 65: 45-48.

  90. Decker A M, Taichman L S, D'Silva N J, Taichman R S. Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 2018 Mar; 5: 7-12.

  91. Harding J. Dental care of cancer patients before, during and after treatment. Br Dent J Team 2017; DOI: 10.1038/bdjteam.2017.8.

  92. Radfar L, Admadabadi R E, Masood F, Scofield R H. Biological Therapy and Dentistry: A review paper. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 594-601.

  93. Newsome P N, Cramb R, Davison S M et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67: 6-19.

  94. Georgakopoulou E A, Scully C. Orofacial adverse effects of biological agents. J Investig Clin Dent 2014;DOI: 10.1111/jicd.12102.

Download references

Author information

Authors and Affiliations

  1. Specialist Registrar (Oral Surgery), Oral Surgery Department, Queen Alexandra Hospital, Portsmouth, PO6 3LY, UK

    Rebecca King

  2. Specialist Registrar (Oral Surgery), Oral Surgery Department, The Royal London Hospital, E1 1BB, UK

    Lara Zebic

  3. Consultant (Oral Surgery), Fl 23 Oral Surgery Department, Guy’s Dental Hospital, London, SE1 9RT, UK

    Vinod Patel

Authors
  1. Rebecca King
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lara Zebic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vinod Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinod Patel.

Ethics declarations

There are no conflicts of interest from any of the authors listed in this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

King, R., Zebic, L. & Patel, V. Deciphering novel chemotherapy and its impact on dentistry. Br Dent J 228, 415–421 (2020). https://doi.org/10.1038/s41415-020-1365-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41415-020-1365-5

This article is cited by

Search

Advanced search

Quick links